ArticleMolecules (Basel, Switzerland)2023
Naphtalimide-Based Bipolar Derivatives Enabling High-Efficiency OLEDs.
Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An Eight-Membered Ring Molecular Framework Based on Carbazole for the Development of Electroluminescent Materials.Molecules (Basel, Switzerland) · 2025Article
- Design and Enzyme-Targeted Assessment of 1,2,4-Triazole-1,8-Naphthalimide Hybrids in Drug Discovery.BioMed research international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Organic light-emitting diodes (OLEDs) have revolutionized the world of technology, making significant contributions to enhancing our everyday lives. With their exceptional display and lighting capabilities, OLEDs have become indispensable in various industries such as smartphones, tablets, televisions, and automotives. They have emerged as a dominant technology, inspiring continuous advancements, and improvements. Taking inspiration from the remarkable advancements in OLED advancements, we have successfully developed naphtalimide-based compounds, namely RB-08, RB-09, RB-10, and RB-11. These compounds exhibit desirable characteristics such as a wide bandgap, high decomposition temperatures (306-366 °C), and very high glass transition temperatures (133-179 °C). Leveraging these exceptional properties, we have harnessed these compounds as green emitters in the aforementioned devices. Among the various fabricated OLEDs, the one incorporating the RB-11 emitter has exhibited superior performance. This specific configuration achieved maximum power efficacy of 7.7 lm/W, current efficacy of 7.9 cd/A, and external quantum efficiency of 3.3%. These results highlight the outstanding capabilities of our synthesized emitter and its potential for further advancements in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.